AstraZeneca PLC, a large-cap Pharmaceutical stock, moved 0.4% this morning. Here are some facts about the company that we're keeping an eye on:
-
AstraZeneca PLC has logged a -2.6% 52 week change, compared to 24.0% for the S&P 500
-
AZN has an average analyst rating of buy and is -20.08% away from its mean target price of $82.81 per share
-
Its trailing earnings per share (EPS) is $1.89, which brings its trailing Price to Earnings (P/E) ratio to 35.0. The Health Care sector's average P/E ratio is 30.21
-
The company's forward earnings per share (EPS) is $4.3 and its forward P/E ratio is 15.4
-
The company has a Price to Book (P/B) ratio of 2.76 in contrast to the Health Care sector's average P/B ratio is 4.08
-
AZN has reported YOY quarterly earnings growth of -16.2% and gross profit margins of 0.9%
-
The company's free cash flow for the last fiscal year was $5.23 Billion and the average free cash flow growth rate is 0.3%
-
AstraZeneca PLC's revenues have an average growth rate of -1.7% with operating expenses growing at -2.0%. The company's current operating margins stand at 21.3%